Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas

Neoplasia (United States)

Volumn 15, Issue 4, 2013, Pages 435-447

  Shankavaram, Uma ^a   Fliedner, Stephanie M J ^a,b,c   Elkahloun, Abdel G ^d   Barb, Jenifer J ^e   Munson, Peter J ^e   Huynh, Thanh T ^b   Matro, Joey C ^b   Turkova, Hana ^b   Marston Linehan, W ^a   Timmers, Henri J ^f   Tischler, Arthur S ^g   Powers, James F ^g   de Krijger, Ronald ^h   Baysal, Bora E ⁱ   Takacova, Martina ^j   Pastorekova, Silvia ^j   Gius, David ^a,k   Lehnert, Hendrik ^b   Camphausen, Kevin ^a   Pacak, Karel ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g TUFTS MEDICAL CENTER   (United States)

^h JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j INSTITUTE OF VIROLOGY   (Slovakia)

^k NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; SOMATOMEDIN C RECEPTOR; STROMELYSIN; SUCCINATE DEHYDROGENASE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR TWIST; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON HIPPEL LINDAU PROTEIN;

ARTICLE; BIOINFORMATICS; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE LOCATION; GENOTYPE; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER FIBROSIS; MALE; MICROARRAY ANLAYSIS; OXIDATIVE PHOSPHORYLATION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84875640167     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.122132     Document Type: Article

References (57)

1. Welander J, Soderkvist P, and Gimm O (2011). Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 18, R253-R276.
2. Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT, and Pacak K (2012). Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 367, 922-930.
3. Fishbein L and Nathanson KL (2012). Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 205, 1-11.
4. Kaelin WG Jr (2004). The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10, 6290S-6295S.
5. Guzy RD, Sharma B, Bell E, Chandel NS, and Schumacker PT (2008). Loss of the SdhB, but not the SdhA, subunit of complex II triggers reactive oxygen speciesdependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 28, 718-731.
6. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, et al. (2005). Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14, 2231-2239.
7. Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, Benit P, Giscos-Douriez I, De Reynies A, Bertherat J, Badoual C, et al. (2009). The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One 4, e7094.
8. Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, Munoz I, Schiavi F, Montero-Conde C, de Cubas AA, Ramires R, Landa I, Leskela S, et al. (2010). Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 24, 2382-2391.
9. Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, et al. (2011). Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 20, 3974-3985.
10. Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N, Boussion M, Travers C, Simian C, Burnichon N, et al. (2012). A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res 44, 359-366.
11. Lefebvre S, Borson-Chazot F, Boutry-Kryza N, Wion N, Schillo F, Peix JL, Brunaud L, Finat A, Calender A, and Giraud S (2012). Screening of mutations in genes that predispose to hereditary paragangliomas and pheochromocytomas. Horm Metab Res 44, 334-338.
12. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacche M, Mori L, Pignataro V, Bernini G, Giache V, Bacca A, et al. (2009). Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab 94, 1541-1547.
13. Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, Schiavi F, Falcioni M, Kwok P, Bauters C, et al. (2009). Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res 69, 3650-3656.
14. Hensen EF, Siemers MD, Jansen JC, Corssmit EP, Romijn JA, Tops CM, van der Mey AG, Devilee P, Cornelisse CJ, Bayley JP, et al. (2011). Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. Clin Endocrinol (Oxf) 75, 650-655.
15. Kim K, Zakharkin SO, and Allison DB (2010). Expectations, validity, and reality in gene expression profiling. J Clin Epidemiol 63, 950-959.
16. Fliedner SM, Breza J, Kvetnansky R, Powers JF, Tischler AS, Wesley R, Merino M, Lehnert H, and Pacak K (2010). Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. Cell Tissue Res 340, 607-612.
17. R Development Core Team (2012). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, Available at: http://www.R-project.org.
18. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, et al. (2006). Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 66, 5278-5286.
19. Tusher VG, Tibshirani R, and Chu G (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98, 5116-5121.
20. Tibshirani R, Hastie T, Narasimhan B, and Chu G (2002). Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99, 6567-6572.
21. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, et al. (2007). Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6, 820-832.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545-15550.
23. Waldmann J, Slater EP, Langer P, Buchholz M, Ramaswamy A, Walz MK, Schmid KW, Feldmann G, Bartsch DK, and Fendrich V (2009). Expression of the transcription factor snail and its target gene twist are associated with malignancy in pheochromocytomas. Ann Surg Oncol 16, 1997-2005.
24. Loriot C, Burnichon N, Gadessaud N, Vescovo L, Amar L, Libe R, Bertherat J, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP, et al. (2012). Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab 97, E954-E962.
25. Hensen EF, Goeman JJ, Oosting J, Van der Mey AG, Hogendoorn PC, Cremers CW, Devilee P, and Cornelisse CJ (2009). Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis. BMC Medical Genomics 2, 25-35.
26. van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP, Smit JW, Romijn JA, and Corssmit EP (2010). Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab 95, 209-214.
27. Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, Bornstein SR, Tiebel O, Adams K, Bratslavsky G, et al. (2011). Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 57, 411-420.
28. Fliedner SM, Kaludercic N, Jiang XS, Hansikova H, Hajkova Z, Sladkova J, Limpuangthip A, Backlund PS, Wesley R, Martiniova L, et al. (2012). Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights froma mouse cellmodel applied to human tumor tissue. PLoSOne 7, e40949.
29. Semenza GL (2007). HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 39, 231-234.
30. Qu A, Taylor M, Xue X, Matsubara T, Metzger D, Chambon P, Gonzalez FJ, and Shah YM (2011). Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology 54, 472-483.
31. Schietke RE, Hackenbeck T, Tran M, Gunther R, Klanke B, Warnecke CL, Knaup KX, Shukla D, Rosenberger C, Koesters R, et al. (2012). Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts. PLoS One 7, e31034.
32. Grosfeld A, Stolze IP, Cockman ME, Pugh CW, Edelmann M, Kessler B, Bullock AN, Ratcliffe PJ, and Masson N (2007). Interaction of hydroxylated collagen IV with the von Hippel-Lindau tumor suppressor. J Biol Chem 282, 13264-13269.
33. Kurban G, Duplan E, Ramlal N, Hudon V, Sado Y, Ninomiya Y, and Pause A (2008). Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV α 2. Oncogene 27, 1004-1012.
34. Kurban G, Hudon V, Duplan E, Ohh M, and Pause A (2006). Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 66, 1313-1319.
35. Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell J, et al. (2006). Expression of HIF-1α, HIF-2α (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 91, 4593-4598.
36. MoraisC, GobeG, JohnsonDW, andHealyH(2011). The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol 43, 1537-1549.
37. Pacak K, Sirova M, Giubellino A, Lencesova L, Csaderova L, Laukova M, Hudecova S, and Krizanova O (2012). NF-κB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. Int J Cancer 131, 2445-2455.
38. Sourbier C, Danilin S, Lindner V, Steger J, Rothhut S, Meyer N, Jacqmin D, Helwig JJ, Lang H, and Massfelder T (2007). Targeting the nuclear factor-κB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 67, 11668-11676.
39. Favier J, Igaz P, Burnichon N, Amar L, Libe R, Badoual C, Tissier F, Bertherat J, Plouin PF, Jeunemaitre X, et al. (2012). Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol 23, 34-42.
40. Takekoshi K, Isobe K, Yashiro T, Hara H, Ishii K, Kawakami Y, Nakai T, and Okuda Y (2004). Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci 74, 863-871.
41. Au PY, Martin N, Chau H, Moemeni B, Chia M, Liu FF, Minden M, and Yeh WC (2005). The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF. Oncogene 24, 3196-3205.
42. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, et al. (2009). Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 94, 386-391.
43. Fottner C, Minnemann T, Kalmbach S, and Weber MM (2006). Overexpression of the insulin-like growth factor I receptor in human pheochromocytomas. J Mol Endocrinol 36, 279-287.
44. Yuen JS, Cockman ME, Sullivan M, Protheroe A, Turner GD, Roberts IS, Pugh CW, Werner H, and Macaulay VM (2007). The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 26, 6499-6508.
45. Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, Protheroe AS, and Macaulay VM (2009). Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 8, 1448-1459.
46. Ilvesmaki V, Liu J, Heikkila P, Kahri AI, and Voutilainen R (1998). Expression of insulin-like growth factor binding protein 1-6 genes in adrenocortical tumors and pheochromocytomas. Horm Metab Res 30, 619-623.
47. Fernandez MC, Venara M, Nowicki S, Chemes HE, Barontini M, and Pennisi PA (2012). Igf-I regulates pheochromocytoma cell proliferation and survival in vitro and in vivo. Endocrinology 153, 3724-3734.
48. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS, and Elkahloun AG (2004). Distinct gene expression profiles in norepinephrine-and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 11, 897-911.
49. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG Jr, et al. (2005). Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8, 155-167.
50. Aprelikova O, Chandramouli GV, Wood M, Vasselli JR, Riss J, Maranchie JK, Linehan WM, and Barrett JC (2004). Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem 92, 491-501.
51. Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H, Forssell-Aronsson E, and Nilsson O (2003). Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 89, 1383-1388.
52. Saveanu A, Muresan M, De Micco C, Taieb D, Germanetti AL, Sebag F, Henry JF, Brunaud L, Enjalbert A, Weryha G, et al. (2011). Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas. Endocr Relat Cancer 18, 287-300.
53. Huynh TT, Pacak K, Brouwers FM, Abu-Asab MS, Worrell RA, Walther MM, Elkahloun AG, Goldstein DS, Cleary S, and Eisenhofer G (2005). Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol 153, 551-563.
54. Nurse CA and Vollmer C (1997). Role of basic FGF and oxygen in control of proliferation, survival, and neuronal differentiation in carotid body chromaffin cells. Dev Biol 184, 197-206.
55. Hofsli E, Wheeler TE, Langaas M, Laegreid A, and Thommesen L (2008). Identification of novel neuroendocrine-specific tumour genes. Br J Cancer 99, 1330-1339.
56. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, et al. (2007). Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007.
57. Tamura K, Makino A, Hullin-Matsuda F, Kobayashi T, Furihata M, Chung S, Ashida S, Miki T, Fujioka T, Shuin T, et al. (2009). Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res 69, 8133-8140.